2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs

Jan 21, 2025 · 2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs Move over, Novo Nordisk and Eli Lilly. Why Pfizer and Roche look like top choices for investors.

CouponFollow Extension

$4
OFF

Sales Balloon For GLP-1s For Obesity From Novo Nordisk, Eli Lilly

3 weeks from now

Nov 7, 2024 · Nearly $4 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity. Novo’s GLP-1 drug, …

bioworld.com

$58
OFF

Eli Lilly's SWOT Analysis: Stock Soars On GLP-1 Success, Faces ... - MSN

3 weeks from now

Eli Lilly's 2025 revenue guidance of $58-$61 billion is ambitious and relies heavily on the continued success of its GLP-1 franchise. Several factors could impede the company's ability …

msn.com

FAQs about 2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs Coupon?

Who owns GLP-1 drugs?

The mass interest in GLP-1 drugs has led to a business boom for the two dominant pharmaceutical players in this space, Lilly and Novo Nordisk, which sold over $7.3 billion worth of its GLP-1 drugs in the first three months of the year. ...

How much will GLP-1 drugs make in 2031?

With GLP-1 drugs set to generate north of $120 billion in annual sales globally by 2031, according to the analysts' estimates, that 20% share could mean close to $25 billion in annual revenues. ...

Which oral GLP-1 agonists can capture a significant share of the market?

1. Orforglipron: This oral GLP-1 agonist in development could potentially capture a significant share of the market by offering a more convenient alternative to injectable GLP-1 therapies. 2. ...

Will new GLP-1 drugs be a 'first-in-class' treatment for obesity?

Multiple companies are aiming to ride this wave by developing new GLP-1 drugs, some of which include next-generation medicines with multiple drug targets. Others, such as Antag Therapeutics in Denmark, are not going directly after GLP-1 but rather other related targets to develop first-in-class treatments for obesity. ...

Should you invest in GLP-1 drugs?

Whether or not GLP-1 drugs are widely adopted across the U.S. and internationally, markets can be driven by emotion and hype—which lends itself to active investing, sizing positions appropriately to account for evolving risks and uncertainties. Among the areas we’ll be monitoring: Insurance and managed care. ...

How many people have taken GLP-1 drugs?

A survey released by KFF this week found that one in eight adults said they’ve taken a GLP-1 drug, which are currently targeted for patients with diabetes, obesity and heart disease, and over 80% have at least heard of them. ...